Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, is attached herewith

233/LG/SE/AUG/2026/GBSL August 12, 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Business Responsibility & Sustainability Report for the Financial Year 2025-26 Dear Sir/Madam, Pursuant to Regulation 34(2)(f) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Business Responsibility & Sustainability Report of the Company for the Financial Year 2025-26, which also forms part of the Annual Report 2025-26. Kindly take the same on your record. Thanking you, Yours faithfully, For Gufic Biosciences Limited Ami Shah Company Secretary Membership No.: A39579 Encl.: As above BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORTING FOR THE FINANCIAL YEAR 2025-26 DIRECTORSMESSAGE: Dear Stakeholders, It gives me great pleasure to present the Company's Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This Report reflects our continued commitment to conducting business responsibly, strengthening our governance practices and creating sustainable value for all our stakeholders. At Gufic, we believe that responsible business practices form the foundation of sustainable growth. While remaining focused on delivering quality products and operational excellence, we continue to strengthen our efforts towards environmental stewardship, employee health and safety, ethical business conduct and meaningful community development through our CSRinitiatives. The evolving ESG landscape presents new opportunities and responsibilities for businesses to enhance transparency, strengthen governance and integrate sustainability into decision-making. We remain committed to meeting these evolving expectations through robust compliance practices, responsible resource management and a culture of integrity and accountability. During the year, we continued to reinforce our governance framework, promote responsible business practices and focus on the efficient use of resources, regulatory compliance, employee well-being and stakeholder engagement. These efforts reflect our commitment to creating long-term value while contributing positively to society and the environment. As we move forward, we will continue to adopt a pragmatic and balanced approach towards sustainability, focusing on continuous improvement, responsible growth and long-term value creation. We sincerely thank our shareholders, customers, employees, business partners, regulators and the communities we serve for their continued trust and support in our journey towards building a responsible and sustainable enterprise. Pranav J. Choksi CEO & Whole Time Director DIN: 00001731 SECTIONA: GENERALDISCLOSURES I. Details of the Listed Company 1 Corporate Identity Number (CIN) of the listed entity L24100MH1984PLC033519 2 Name of the listed entity Gufic Biosciences Limited 3 Year of incorporation 23/07/1984 4 Registered office address 37, First Floor, Kamala Bhavan- II, S. Nityanand Road, Andheri-East, Mumbai - 400069 5 Corporate address SMHouse, 11 Sahakar Road, Vile Parle-East, Mumbai - 400057 6 E-mail corporaterelations@guficbio.com 7 Telephone (+91 22) 67261000 8 Website www.gufic.com 9 Financial year for which reporting is being done 1April 2025 to 31March 2026 10 Name of the Stock Exchange(s) where shares BSELimited (Scrip Code: 509079) and National Stock are listed Exchange of India Limited (Scrip Symbol: GUFICBIO) 11 Paid-up Capital ₨ 100,282,506/- 12 Name and contact details (telephone, email address) Ms. Ami Shah, Company Secretary & Compliance Officer, of the person who may be contacted in case of any Email: mgr_legal@guficbio.com, queries on the BRSR report. Tel. No.: 022 67261000 13 Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity Standalone basis and all the entities which form a part of its consolidated financial statements, taken together) 14 Name of assurance provider None 15 Type of assurance obtained Not applicable II. Products/services 16. Details of business activities (accounting for 90% of the turnover): Sr. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1 Pharmaceutical Manufacturing and marketing of 100 pharmaceutical products 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Sr. No. Product/Service NICCode % of total Turnover contributed 1 Manufacture of pharmaceutical products 210 100 III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 3 28* 31 International 0 3 3 *No. of offices includes the place of business of Company's Carrying and Forwarding Agents. 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 28 States & 8 Union Territories International (No. of Countries) 70+ Countries b. What is the contribution of exports as a percentage of the total turnover of the entity? As on March 31, 2026, the exports of the Company contributes to 23.07% . c. Abrief on types of customers Our customers include wholesalers, distributors, pharmacy chains, hospitals, government institutions and other pharmaceutical companies. Patients who use our products are our ultimate customers. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled) : Sr. No. Particulars Total (A) Male Female No. (B) % (B/A) No. ( C ) % (C/A) EMPLOYEE 1 Permanent (D) 1567 1345 85.83 222 14.17 2 Other than Permanent (E) 387 356 91.99 31 8.01 3 Total employees (D + E) 1954 1701 87.05 253 12.95 WORKER 4 Permanent (F) 40 36 90.00 4 10.00 5 Other than Permanent (G) 909 557 61.28 352 38.72 6 Total Workers (F + G) 949 593 62.49 356 37.51 b. Differently abled Employees and workers: Sr. No. Particulars Total (A) Male Female No. (B) % (B/A) No. ( C ) % (C/A) DIFFERENTLYABLEDEMPLOYEES 1 Permanent (D) - - - - - 2 Other than Permanent (E) - - - - - Total differently abled - - - - - employees (D + E) DIFFERENTLYABLEDWORKERS 3 Permanent (F) - - - - - 4 Other than Permanent (G) - - - - - Total differently abled - - - - - employees (F + G) 21. Participation / Inclusion / Representation of women Total (A) No. and percentage of Females No. (B) % (B / A) Board of Directors 6 1 16.67% Key Management Personnel* 2 1 50.00% * The Key Managerial Personnel (KMP's) includes Chief Financial Officer and Company Secretary as the other KMP's are already included under the heading "Board of Directors". 22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) FY 2025-26 FY 2024-25 FY 2023-24 (Turnover (Turnover rate in (Turnover rate in rate in the year prior current FY) previous FY) to the previous FY) Male Female Total Male Female Total Male Female Total Permanent Employees 21.12 18.04 20.73 21.98 17.29 21.40 17.79 23.15 18.45 Permanent Workers 0 0 0 0 0 0 0 0 0 Notes: Trainees and non-confirmed employees are excluded from the calculaon of the turnover rate. V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures S.No. Name of the holding / Indicate whether % of shares Does the enty indicated at subsidiary /associate holding/ Subsidiary/ held by column A, parcipate in the companies / joint Associate/ Joint listed enty Business Responsibility iniaves ventures (A) Venture of the listed enty? (Yes/No) 1 Gufic UK Limited Subsidiary 100 No 2 Gufic Prime Private Limited Subsidiary 60 No 3 Veira Life FZE Subsidiary 100 No 4 Gufic Ireland Limited Subsidiary 100 No VI. CSR Details 24. i) Whether CSR is applicable as per sec [Showing first 8,000 characters — download PDF for full document]